ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-El

Preamble......237 Medicine is experiencing an unprecedented focus on quantifying and improving health care quality. The American College of Cardiology (ACC) and the American Heart Association (AHA) have developed a multi-faceted strategy to facilitate the process of improving clinical care. The

[1]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[2]  K. Eagle,et al.  Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. , 2007, JAMA.

[3]  Harlan M Krumholz,et al.  ACC/AHA Clinical Performance Measures for Adults with Chronic Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures): endorsed by the Heart Failure Society , 2005, Circulation.

[4]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .

[5]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[6]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[7]  J. W. Schaeffer,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article , 2002 .

[8]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[9]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[10]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[11]  R. Califf,et al.  Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. , 2005, JAMA.

[12]  J. Ornato,et al.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). , 2004, Circulation.

[13]  S. Ebrahim,et al.  Exercise‐based Rehabilitation for Coronary Heart Disease , 2001, The Cochrane database of systematic reviews.

[14]  R. Califf,et al.  Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. , 2006, Archives of internal medicine.

[15]  Alastair Baker,et al.  Crossing the Quality Chasm: A New Health System for the 21st Century , 2001, BMJ : British Medical Journal.

[16]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[17]  Deepak L. Bhatt,et al.  Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. , 2006, Archives of internal medicine.

[18]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[19]  V. Fuster,et al.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.

[20]  Jeffrey L. Anderson,et al.  2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[21]  C. Furberg,et al.  Sex bias and underutilization of lipid-lowering therapy in patients with coronary artery disease at academic medical centers in the United States and Canada. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) Investigators. , 2000, Archives of internal medicine.

[22]  K. Alexander,et al.  Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.

[23]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[24]  R L Brown,et al.  Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. , 1998, Archives of internal medicine.

[25]  L. Køber,et al.  Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarction , 1999, The Lancet.

[26]  K. Alexander,et al.  Enoxaparin dosing and associated risk of in-hospital bleeding and death in patients with non ST-segment elevation acute coronary syndromes. , 2007, Archives of internal medicine.

[27]  S. Zyzanski,et al.  Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. , 1998, Circulation.

[28]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[29]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[30]  Nick Freemantle,et al.  β Blockade after myocardial infarction: systematic review and meta regression analysis , 1999 .

[31]  S. Normand,et al.  Measuring performance for treating heart attacks and heart failure: the case for outcomes measurement. , 2007, Health affairs.

[32]  V. Fuster,et al.  AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Journal of the American College of Cardiology.

[33]  Christopher E. Buller,et al.  2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2008, Circulation.

[34]  B. Rifkind,et al.  The value of lowering cholesterol after myocardial infarction. , 1990, The New England journal of medicine.

[35]  W. Rogers,et al.  Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. , 1991, Circulation.

[36]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[37]  Constance K Haan,et al.  Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.

[38]  J. Alpert,et al.  Universal definition of myocardial infarction. , 2007, European heart journal.

[39]  S. Normand,et al.  American College of Cardiology and American Heart Association Methodology for the Selection and Creation of Performance Measures for Quantifying the Quality of Cardiovascular Care , 2005 .

[40]  S. Grundy,et al.  Cholesterol Lowering in the Elderly Population , 1999 .

[41]  I. Piña,et al.  AACVPR/ACC/AHA 2007 performance measures on cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary prevention services. , 2007, Journal of cardiopulmonary rehabilitation and prevention.

[42]  R. Collins,et al.  Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[43]  Sidney C. Smith,et al.  Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. , 1999, The American journal of cardiology.

[44]  A. Jha,et al.  Care in U.S. hospitals--the Hospital Quality Alliance program. , 2005, The New England journal of medicine.

[45]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[46]  J. Gurwitz,et al.  Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease , 1999, Journal of General Internal Medicine.

[47]  J. Cleeman,et al.  Cholesterol lowering as a treatment for established coronary heart disease. , 1992, Circulation.

[48]  Jerod M. Loeb,et al.  Quality of Care in U.S. Hospitals as Reflected by Standardized Measures, 2002-2004 , 2005 .

[49]  Bittner,et al.  Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. , 1997, JAMA.

[50]  Rowena J Dolor,et al.  Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. , 2007, Journal of the American College of Cardiology.

[51]  R. Rosenson,et al.  Myocardial injury: the acute phase response and lipoprotein metabolism. , 1993, Journal of the American College of Cardiology.

[52]  A. Maggioni,et al.  Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data , 2001, Heart.

[53]  C. Gross,et al.  Adoption of Spironolactone Therapy for Older Patients With Heart Failure and Left Ventricular Systolic Dysfunction in the United States, 1998–2001 , 2005, Circulation.

[54]  S. Ebrahim,et al.  Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.

[55]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[56]  Pamela S Douglas,et al.  Acc/aha/ase 2003 Guideline Update for the Clinical Application of Echocardiography: Summary Article a Report of the American College of Cardiology/american Heart Association Task Force on Practice Guidelines (acc/aha/ase Committee to Update the 1997 Guidelines for the Clinical Application of Echocar , 2003 .

[57]  V. Fuster,et al.  Preventing heart attack and death in patients with coronary disease. , 1995, Circulation.

[58]  S. Oparil,et al.  Guide to Preventive Cardiology for Women , 1999 .

[59]  G. Lamas,et al.  Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.

[60]  E. Braunwald.  Acute myocardial infarction--the value of being prepared. , 1996, The New England journal of medicine.

[61]  Lisa Hartling,et al.  Meta-Analysis: Secondary Prevention Programs for Patients with Coronary Artery Disease , 2005, Annals of Internal Medicine.